Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | GCK | P35557 | 7/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9895365 | 0.94 | EPHX2 (0.41) | EPHX2GCKROCK2NAMPTFFAR2 | |
| SCHEMBL9895023 | 0.89 | PTPN1 (0.45) | EPHX2GCKFFAR2PTPN1 | |
| SCHEMBL9895818 | 0.89 | PTPN1 (0.45) | EPHX2GCKFFAR2PTPN1 | |
| SCHEMBL9896000 | 0.88 | AKT1 (0.43) | EPHX2GCKAKT1PIK3CAMTOR | |
| SCHEMBL9894828 | 0.87 | FFAR2 (0.45) | EPHX2GCKAKT1PIK3CAMTOR | |
| SCHEMBL9894922 | 0.86 | XDH (0.41) | EPHX2GCKAKT1PIK3CAMTOR | |
| SCHEMBL9895191 | 0.86 | GCK (0.40) | EPHX2GCKAKT1PIK3CAMTOR | |
| SCHEMBL9895303 | 0.85 | FFAR2 (0.48) | GCKAKT1PIK3CAMTORFFAR2 | |
| SCHEMBL9894921 | 0.85 | FFAR2 (0.43) | EPHX2GCKFFAR2CYP2C9 | |
| SCHEMBL9896267 | 0.84 | SMN1; SMN2 (0.42) | GCKFFAR2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149718-A1 | Amido Compounds | BROTHERTON-PLEISS CHRISTINE E (US) | 2012-06-14 | — | — | US | claimed |
| US-20120149718-A1 | Amido Compounds | BROTHERTON-PLEISS CHRISTINE E (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149718-A1 | Amido Compounds | BROTHERTON-PLEISS CHRISTINE E (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149718-A1 | Amido Compounds | P2RX7, P2RX3, P2RX2 | EPHX2 1765/4885GCK 1756/4885ROCK2 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.